; Whereas, through COVAX, Gavi and global partners delivered nearly 2,000,000,000 doses of COVID–19 vaccines to 146 economies, and averted an estimated 2,700,000 deaths in Advance Market Commitment lower-income participating economies; Whereas Gavi is providing additional vaccine support to address health service interruptions that occurred during the COVID–19 pandemic and contributed to the largest backslide in routine childhood immunization in 30 years, and is also focusing on the 14,000,000 zero-dose children in Gavi-supported countries who had not received a single vaccine; Whereas vaccines programs are widely regarded as high-impact, evidence-based interventions and are among the most efficient, cost-effective, and successful health initiatives in history, returning over $50 in health and economic savings for every $1 invested in Gavi-supported countries; Whereas the prevention of infectious disease through immunization in Gavi-eligible countries provides protection and health security in the United States by reducing the prevalence of infectious diseases and stemming outbreaks at their source; Whereas United States investment in Gavi complements and enhances the effectiveness of other United States investments in global health, particularly in maternal and child health and nutrition; Whereas Gavi is committed to working with partners, including United States bilateral programs administrated by the United States Agency for International Development (USAID) and the Centers for Disease Control and Prevention (CDC), to ensure children in developing nations have access to lifesaving vaccines and immunizations; Whereas Gavi’s next strategic cycle will cover the strategic period of 2026 to 2030, which will include the expansion of Gavi’s malaria program; Whereas the launches of the Gavi’s Investment Opportunity for 2026 through 2030 and AVMA will be held in June 2024 and co-hosted by the Government of France, African Union, and Africa CDC to obtain funding commitments